共 114 条
[1]
Teshome M(2014)Neoadjuvant therapy in the treatment of breast cancer Surg Oncol Clin N Am. 23 505-523
[2]
Hunt KK(2015)Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy Nat Rev Clin Oncol. 12 335-343
[3]
King TA(2016)Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients Am J Surg. 212 969-981
[4]
Morrow M(2013)Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): A prospective, multicentre cohort study Lancet Oncol. 14 609-618
[5]
El Hage Chehade H(2015)Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: The SN FNAC study J Clin Oncol. 33 258-263
[6]
Headon H(2013)Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the american college of surgeons oncology group (ACOSOG) Z1071 clinical trial JAMA. 310 1455-1461
[7]
El Tokhy O(2015)Estrogen Receptor Status and the Future Burden of Invasive and In Situ Breast Cancers in the United States J Natl Cancer Inst. djv107 159-724
[8]
Heeney J(2014)Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics Cancer Epidemiol Biomarkers Prev. 23 714-3509
[9]
Kasem A(2016)Nomograms for predicting axillary response to neoadjuvant chemotherapy in clinically node-positive patients with breast cancer Ann Surg Oncol. 23 3501-3685
[10]
Mokbel K(2005)Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer J Clin Oncol. 23 3676-1281